Bicyclic protein kinase inhibitors

Details Bicyclic protein kinase inhibitors Bicyclic protein kinase inhibitors

2007-03-13

2007-03-13

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252040, C544S236000

Reexamination Certificate

active

10725267

ABSTRACT:
The present invention relates to novel 3-hetero-arylidene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

REFERENCES:
patent: 4002749 (1977-01-01), Rovnyak
patent: 4053613 (1977-10-01), Rovnyak et al.
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5196446 (1993-03-01), Levitzki et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5322950 (1994-06-01), Sircar et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5397787 (1995-03-01), Buzzetti et al.
patent: 5534515 (1996-07-01), Grundler
patent: 5786488 (1998-07-01), Tang et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5880141 (1999-03-01), Tang et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: RE36256 (1999-07-01), Spada et al.
patent: 6063782 (2000-05-01), Kimura et al.
patent: 6313158 (2001-11-01), Tang et al.
patent: 6316635 (2001-11-01), Tang et al.
patent: 6395734 (2002-05-01), Tang et al.
patent: 6465507 (2002-10-01), Tang et al.
patent: 6486185 (2002-11-01), McMahon et al.
patent: 6635640 (2003-10-01), Tang et al.
patent: 6642232 (2003-11-01), Mattson et al.
patent: 6677368 (2004-01-01), Cui et al.
patent: 0 252 713 (1988-01-01), None
patent: 0 566 226 (1993-10-01), None
patent: 1.398.224 (1965-05-01), None
patent: 3899/92 (1992-12-01), None
patent: WO 91/13055 (1991-09-01), None
patent: WO 91/15495 (1991-10-01), None
patent: WO 92/07830 (1992-05-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 92/21660 (1992-12-01), None
patent: WO 93/23040 (1993-11-01), None
patent: WO 94/03427 (1994-02-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/14808 (1994-07-01), None
patent: WO 95/14667 (1995-06-01), None
patent: WO 95/24190 (1995-09-01), None
patent: WO 96/00226 (1996-01-01), None
patent: WO 96/16964 (1996-06-01), None
patent: WO 96/22976 (1996-08-01), None
patent: WO 96/40116 (1996-12-01), None
patent: WO 98/07695 (1998-02-01), None
patent: WO 98/07835 (1998-02-01), None
patent: WO 98/45708 (1998-10-01), None
patent: WO 98/50356 (1998-11-01), None
patent: WO 98/56376 (1998-12-01), None
patent: WO 99/10325 (1999-03-01), None
Akbasak and Sunar-Akbasak, “Oncogenes: cause or consequence in the development of glial tumors,”J. Neurol. Sci. 111:119-133 (1992) © Elsevier Science Publishers .
Andreani et al., “Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones,”Eur. J. Med. Chem. 32:919-924 (1997) © Elsevier, Paris.
Andreani et al., “In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones,”Arzneimittel-Forschung Drug Research48:727-729 (1998) © .
Arteaga et al., “Blockade of the Type 1 Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice,”J. Clin. Invest. 84:1418-1423 (1989) copyright The American Society for Clinical investigation, Inc.
Arvidsson et al., “Tyr-716 in the Platelet-Derived Growth Factor β-Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation,”Molecular and Cellular Biology14:6715-6726 (1994) © The American Society for Microbiology.
Baserga, “Oncogenes and the Strategy of Growth Factors,”Cell79:927-930 (1994) © Cell Press.
Baserga, “The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?”Cancer Research55:249-252 (1995).
Beilstein Reg. No. 252929 (1998).
Bolen et al., “The Src family of tyrosine protein kinases in hemopoietic signal transduction,”Faseb J.6:3403-3409 (1992).
Bolen, “Nonreceptor tyrosine protein kinases,”Oncogene8:2025-2031 (1993) copyright MacMillan Press Ltd.
Bonner et al., “Structure and Biological Activity of Human Homologs of theraf/milOncogene,”Molecular and Cellular Biology5:1400-1407 (1985) © The American Society for Microbiology.
Buzzetti et al., “Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases,”II Farmaco48:615-636 (1993).
Cance et al., “Novel Protein Kinases Expressed in Human Breast Cancer,”Int. J. Cancer54:571-577 (1993) © Wiley-Liss, Inc.
Carpenedo et al., “Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs,”Analytical Biochemistry244:74-79 (1997) © Academic Press, Inc.
Chen et al., “Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on γ-Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron,”Chinese Journal of Physiology40:149-156 (1997).
Claesson-Welsh, “Signal Transduction by the PDGF Receptors,”Progress in Growth Factor Research5:37-54 (1994) © Elsevier Science Ltd.
Coppola et al., “A Functional Insulin-Like Growth Factor I Receptor Is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor,”Molecular and Cellular Biology14:4588-4595 (1994) © The American Society for Microbiology.
Damiani et al., “Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals,”Biochemical Pharmacology48:1155-1161 (1994) copyright Elsevier Science Ltd.
Davis et al., “Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds,”Journal of Medicinal Chemistry16:1043-1045 (1973) © American Chemical Society.
De Vries et al., “The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor,”Science255:989-991 (1992).
Decker and Lohmann-Matthes, “A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity,”J. Immunol. Methods15:61-69 (1988) copyright Elsevier.
Dickson et al., “13. Tyrosine kinase receptor—nuclear protooncogene interactions in breast cancer,”Cancer Treatment Res. 61:249-273 (1992) © Kluwer Academic Publishers.
Fantl et al., “Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways,”Cell69:413-423 (1992) © Cell Press.
Fendly et al., Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2
eu Gene Product,Cancer Research50:1550-1558 (1990); © American Association for Cancer Research.
Ferrara and Henzel, “Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells,”Biochemical and Biophysical Research Communications161:851-858 (1989) © Academic Press, Inc.
Fingl and Woodbury, “Chapter 1—General Principles,” inThe Pharmacological Basis of Therapeutics5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975) © MacMillan Publishing Co. Inc.
Floege et al., “Factors involved in the regulation of mesangial cell proliferationin vitroandin vivo,” Kidney International43:S47-S54 (1993) © International Society of Nephrology.
Folkman and Shing, “Angiogenesis,”J. Biol. Chem. 267:10931-10934 (1992) © The American Society for Biochemistry and Molecular Biology.
Folkman, “Ch. 24. Angiogenesis,”Congress of Thrombosis and Haemostasis(Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987).
Folkman, “Tumor Angiogenesis: Therapeutic Implications,”New England J. Medicine285:1182-1188 (1971).
Folkman, “What is the Evidence that Tumors are Angiogenesis Dependent?”Journal of the National Cancer Institute82:4-6 (1990).
Gazit et al., “Tyrphostins. 2. Heterocyclic and α-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inh

Affiliated with

Also associated with

Rating

Bicyclic protein kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bicyclic protein kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic protein kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3773332